Cyclopentolate

CHEMBL1201338 Phase 4 Approuvé Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
291.4 g/mol
LogP
2.7
Phase
4

An anticholinergic eye drop that temporarily paralyzes the ciliary muscle and dilates the pupil, used to allow detailed examination of the retina and for refraction testing, especially in children. Effects last several hours after instillation.

Masse moléculaire

291,4000 g/mol

LogP

2,70

TPSA

49,80 Ų

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Mécanisme d'action

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Structure 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CN(C)CCOC(=O)C(c1ccccc1)C1(O)CCCC1

InChI

InChI=1S/C17H25NO3/c1-18(2)12-13-21-16(19)15(14-8-4-3-5-9-14)17(20)10-6-7-11-17/h3-5,8-9,15,20H,6-7,10-13H2,1-2H3

Molecular Formula

C17H25NO3

HBD / HBA

1 / 4

Liaisons Rotatives

7

Atomes Lourds

21

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

An anticholinergic eye drop that temporarily paralyzes the ciliary muscle and dilates the pupil, used to allow detailed examination of the retina and for refraction testing, especially in children. Effects last several hours after instillation.

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Yes, Cyclopentolate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201338. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 2905. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.